The Performance and Benefits of Oligonucleotide Synthesis Market: Analysis, Growth, and Trends 2022

The Global Oligonucleotide Synthesis Market was valued at USD 6.3 billion in 2021 and is expected to register a CAGR of 17.6% during the forecast period (2022 – 2026). The report studies the market scenario and its growth prospects during the forecast period. In addition, the report includes a detailed analysis of the leading competitors functioning in this market. In order to calculate the market size, the report considers the sales, value, volume, and exclude new installations, replacement, spares, shipments, aftermarket sales, retrofit, and services market.

The market research report on the Oligonucleotide Synthesis industry analyzes the overall estimates of all the segments and sub-segments of the market, on a global and regional scale. The report presents the historical data for the time period 2017-2021, revenue estimates from 2018-2022, and forecasts from 2021 till 2026. The report presents a detailed analysis of the market trends, market dynamics, leading competitors, technological innovations and inventions, key developments, lucrative opportunities, and future strategies. The market size is calculated on the basis of the financials generated through sales from the mentioned segments and sub-segments in this research study. The overall market has been analyzed using the top-down and bottom-up approaches for data validation and accuracy measures.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350

Prominent Players:

Some of the leading players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), and Agilent Technologies, Inc. (US). The leading players in the oligonucleotide therapeutics market are Biogen Inc. (US) and Sarepta Therapeutics, Inc. (US).

The Global Oligonucleotide Synthesis Market is defined by the presence of some of the leading competitors operating in the market, including the well-established players and new entrants, and the suppliers, vendors, and distributors. The key players are continuously focusing on expanding their geographic reach and broadening their customer base, in order to expand their product portfolio and come up with new advancements. The report also analyzes the development proposals and the feasibility of new investments. This report has been collated in order to provide guidance and direction to the companies and individuals interested in buying this research report.

The study categorizes the oligonucleotide synthesis market into the following segments and subsegments:

Oligonucleotide synthesis Market, by Product

• Oligonucleotide-based Drugs
• Synthesized Oligonucleotides
• By Product
• Primers
• Probes
• DNA Oligos
• RNA Oligos
• Other Synthesized Oligos
• By Type
• Customized Oligos
• Predesigned Oligos
• Reagents
• Equipment

Oligonucleotide synthesis Market, by Application

• Research Applications
• PCR
• Sequencing
• Other Research Applications
• Diagnostic Applications

Therapeutic Applications, By Type

• Antisense Oligonucleotide-based Therapies
• RNAi Oligonucleotide-based Therapies
• CpG Oligonucleotide-based Therapies

Therapeutic Applications, By Disease Type

• Neurological Disorders
• Infectious Diseases
• Other Diseases

Oligonucleotide synthesis Market, by End User

• Hospitals
• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• CROs and CMOs
• Academic Research Institutes

Some of the key geographies mentioned in this report include:

• North America (U.S and Canada and rest of North America)
• Europe (Germany, France, Italy and Rest of Europe)
• Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
• LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

In the decade of the 2020's the B2B world will see $25 trillion worth of disruptive revenue shifts. Organizations globally are navigating both the opportunities and risks that are consequent.